Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Ovarian Cancer
How do you manage patients with germline BRCA mutations who have STIC lesions found at time of risk-reducing BSO?
Related Questions
In a patient with an HR-proficient stage III high-grade serous ovarian cancer s/p R0 primary debulking surgery for whom you are not considering bevacizumab in addition to chemotherapy, would you consider IP chemotherapy?
Would you hold a PARP inhibitor in the perioperative period for an ileostomy reversal in a patient who has completed primary debulking surgery followed by chemotherapy?
Would you favor giving mirvetuximab before paclitaxel/bevacizumab?
What are your top takeaways in Gyn Cancers from ESMO 2024?
Would you ever re-treat recurrent ovarian cancer with mirvetuximab soravtansine if the patient responded to it in the past (e.g., more than 6 months ago)?
How would you manage a patient with an incidental finding of 1 mm focus of high-grade serous carcinoma in the fallopian tube after TAHBSO was done for a benign broad ligament fibroid with negative pelvic washings?
Do you recommend bevacizumab with front-line platinum-based adjuvant chemotherapy for fully resected stage III ovarian clear cell carcinoma?
Would you recommend surgery or stereotactic radiation therapy for a young woman with high-grade serous ovarian cancer presenting with a pelvic LN oligometastasis following maintenance therapy?
Do you test ovarian cancer tumors for targetable biomarkers (e.g., HER2, folate receptor, MMR) at the time of primary diagnosis or at time of recurrence?
How would you approach a patient who is unable to undergo the recommended ophthalmologic examinations during treatment with mirvetuximab soravtansine?
